Product Information
IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $2.6771 per EA under NDC 31722029730. Its NADAC has been published 36 times since Jan 28, 2026.
FDA first approved this application on Apr 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722029730
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA212975FDA Approved
4/14/2025
TE Code
AB
On Market Since
4/14/2025
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 36 times since Jan 28, 2026, and over the history we have for it it has declined 16.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6771 per EA |
|---|---|
| All-time high | $3.2150 (Mar 11, 2026) |
| All-time low | $2.6771 (Sep 23, 2026) |
| 52-week high | $3.2150 |
| 52-week low | $2.6771 |
| Median price | $3.0171 |
| Average price | $3.0214 |
| Largest weekly change | -6.9% (Sep 23, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the IMATINIB MESYLATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
IMATINIB MESYLATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Camber Pharmaceuticals Inc., is $2.6771 per EA (NDC 31722029730), effective Sep 30, 2026.
How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 16.0%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?
Since Jan 28, 2026, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $2.6771 (Sep 23, 2026) to a high of $3.2150 (Mar 11, 2026), with a median of $3.0171 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of IMATINIB MESYLATE 400 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures IMATINIB MESYLATE 400 MG TAB?
IMATINIB MESYLATE 400 MG TAB (NDC 31722029730) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.